Reported 1 day ago
Bicycle Therapeutics plc (NASDAQ:BCYC) received positive analyst ratings following its Q2 2025 results, with RBC Capital raising its price target from $25 to $27 and maintaining an Outperform rating. While updates on one of their programs have been delayed to 2026, their cost-cutting measures are expected to extend financial stability into 2028. The company aims to advance its clinical trials and offers a potentially competitive treatment with its drug zelenectide. Overall, analysts project significant upside potential for the stock.
Source: YAHOO